The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs

Drug Metabolism and Disposition

Volumn 32, Issue 2, 2004, Pages 246-258

  Huskey, Su Er W ^a   Dean, Brian J ^a   Doss, George A ^a   Wang, Zhen ^a   Hop, Cornelis E C A ^a   Anari, Reza ^a   Finke, Paul E ^a   Robichaud, Albert J ^a   Zhang, Minghua ^a   Wang, Bonnie ^a   Strauss, John R ^a   Cunningham, Paul K ^a   Feeney, William P ^a   Franklin, Ronald B ^a   Baillie, Thomas A ^a   Chiu, Shuet Hing L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUORO ALPHA HYDROXYBENZENEACETIC ACID; 4 FLUORO ALPHA OXOBENZENEACETIC ACID; APREPITANT; CARBON 14; CARBOXYLIC ACID DERIVATIVE; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CHEMOTHERAPY INDUCED EMESIS; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; RAT; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; ANTIEMETICS; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DOGS; FECES; GLUCURONIDES; INJECTIONS, INTRAVENOUS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MANDELIC ACIDS; MASS SPECTROMETRY; MORPHOLINES; PHENYLACETATES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; EMESIS;

EID: 10744224396     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.2.246     Document Type: Article

References (27)

1. Ballard TM, Sanger S, and Higgins GA (2001) Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 412:255-264.
2. Beattie DT, Beresford IJ, Connor HE, Marshall FH, Hawcock AB, Hagan RM, Bowers J, Birch PJ, and Ward P (1995) The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol 116:3149-3157.
3. Bountra C, Bunce K, Dale T, Gardner C, Jordan C, Twissell D, and Ward P (1993) Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 249:R3-R4.
4. Campos D, Pereira J, Reinhardt R, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson L, et al. (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767.
5. Cheeta S, Tucci S, Sandhu J, Williams AR, Rupniak NM, and File SE (2001) Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 915:170-175.
6. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, et al. (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835-842.
7. Dean B, Rabe M, Doss G, Arison B, Hop C, Chiu S, and Huskey S (2000) Identification of very polar metabolites of MK-0869 in dog urine. Drug Metab Rev 32:261.
8. Diemunsch P and Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:533-546.
9. Gonsalves S, Watson J, and Ashton C (1996) Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 305:181-185.
10. Gonzalez MI, Field MJ, Holloman EF, Hughes J, Oles RJ, and Singh L (1998) Evaluation of PD 154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain. Eur J Pharmacol 344:115-120.
11. Griebel G (1999) Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 82:1-61.
12. Hale JJ, Mills SG, MacCoss M, Dorn CP, Finke PE, Budhu RJ, Reamer RA, Huskey SE, Luffer-Atlas D, Dean BJ, et al. (2000) Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem 43:1234-1241.
13. Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J, et al. (1998) Structural optimization affording 2-(R)-(1-(R)-3,5-bistrifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-oxo-1,2,4-triazol-5-yl) methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 41:4607-4614.
14. Harrison T, Owens AP, Williams BJ, Swain CJ, Williams A, Carlson EJ, Rycroft W, Tattersall FD, Cascieri MA, Chicchi GG, et al. (2001) An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration. J Med Chem 44:4296-4299.
15. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (Wash DC) 281:1640-1645.
16. Maubach KA, Rupniak NM, Kramer MS, and Hill RG (1999) Novel strategies for pharmacotherapy of depression. Curr Opin Chem Biol 3:481-488.
17. Navari R-M, Reinhardt R-R, Gralla R-J, Kris M-G, Hesketh P-J, Khojasteh A, Kindler H, Grote T-H, Pendergrass K, Grunberg S-M, et al. (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 340:190-195.
18. Rudd JA, Jordan CC, and Naylor RJ (1996) The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119:931-936.
19. Rupniak NM and Kramer MS (1999) Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 20:485-490.
20. Rupniak NM, Tattersall FD, Williams AR, Rycroft W, Carlson EJ, Cascieri MA, Sadowski S, Ber E, Hale JJ, Mills SG, et al. (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur J Pharmacol 326:201-209.
21. Saria A (1999) The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 375:51-60.
22. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, and Erspamer V (2002) The tachykinin peptide family. Pharmacol Rev 54:285-322.
23. Singh L, Field MJ, Hughes J, Kuo BS, Suman-Chauhan N, Tuladhar BR, Wright DS, and Naylor RJ (1997) The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Eur J Pharmacol 321:209-216.
24. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, et al. (2000) The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39:652-663.
25. Urban LA and Fox AJ (2000) NK1 receptor antagonists-are they really without effect in the pain clinic? Trends Pharmacol Sci 21:462-464.
26. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, and Andrews PL (1995) The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 115:84-94.
27. Zaman S, Woods AJ, Watson JW, Reynolds DJ, and Andrews PL (2000) The effect of the NK1 receptor antagonist CP-99,994 on emesis and c-fos protein induction by loperamide in the ferret. Neuropharmacology 39:316-323.